{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'etiology associated with drug exposure should be evaluated to determine possible', 'immune etiology. If an irAE is suspected, efforts should be made to rule out', 'neoplastic, infectious, metabolic, toxin or other etiologic causes prior to labeling', 'an AE as an irAE.', '9.4.3.1.', 'Immune-Related Adverse Events', 'Detailed guidance of management of irAEs is provided in Section 8.3.2 and Appendix 2.', 'NOTE: Regarding irAEs, for any AE that is of a type known to be potentially immune-related', '(eg rash, colitis, elevated transaminases, or endocrine) but is deemed not to be an irAE by the', 'investigator, the sponsor may request additional information.', '9.4.4.', 'Reporting Adverse Events Leading to Withdrawal from the Study', \"All AEs that lead to a patient's withdrawal from the study must be reported to the sponsor's\", 'medical monitor within 30 days.', '9.4.5.', 'Abnormal Laboratory, Vital Signs, or Electrocardiogram Results', 'The criteria for determining whether an abnormal objective test finding should be reported as an', 'AE include:', 'the test result is associated with accompanying symptoms, and/or', 'the test result requires additional diagnostic testing or medical/surgical intervention,', 'and/or', 'the test result leads to a change in dosing (outside of protocol-stipulated dose', 'adjustments), discontinuation from the study, significant additional concomitant drug', 'treatment, or other therapy', 'Contact the medical monitor in the event the investigator feels that an abnormal test finding should', 'be reported as an AE, although it does not meet any of the above criteria.', 'Repeating an abnormal test, in the absence of any of the above conditions, does not constitute an', 'AE. Any abnormal test result that is determined to be an error does not require reporting as an', 'AE.', 'Evaluation of severity of laboratory abnormalities will be assessed according to the scale outlined', 'in Section 9.5.1.', '9.4.6.', 'Follow-up', 'Information for any non-SAE that starts during the treatment period or within 90 days after last', 'treatment will be collected from the time of the event until resolution of the event, or until the', \"patient's last study visit, whichever comes first.\", 'Serious adverse event information will be collected until the event is considered chronic and/or', 'stable.', 'Regeneron Pharmaceuticals, Inc.', 'Page 91 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '9.5.', 'Evaluation of Severity and Causality', '9.5.1.', 'Evaluation of Severity', 'The severity of AEs (including test findings classified as AEs) will be graded using the current', 'version of the NCI-CTCAE grading system. Adverse events not listed in the NCI-CTCAE will be', 'graded according to the following scale:', '1 (Mild):', 'Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only;', 'intervention not indicated.', '2', '(Moderate): Moderate; minimal, local, or noninvasive intervention indicated; limiting', 'age-appropriate instrumental Activities of Daily Living (ADL)*', '3 (Severe): Severe or medically significant but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL **', '4 (Life-threatening): Life-threatening consequences; urgent intervention indicated.', '5 (Death):', 'Death related to AE', '*', 'Instrumental Activities of Daily Living (ADL) refer to preparing meals, shopping for groceries or clothes,', 'using the telephone, managing money, etc.', '**', 'Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications,', 'and not bedridden.', 'If a laboratory value is considered an AE, its severity should be based on the degree of', 'physiological impairment the value indicates.', '9.5.2.', 'Evaluation of Causality', 'Relationship of Adverse Events to Study Drug:', 'The relationship of AEs or SAEs to study drug will be assessed by the investigator, and will be a', 'clinical decision based on all available information. The following question will be addressed:', 'Is there a reasonable possibility that the AE or SAE may have been caused by the study drug?', 'The possible answers are:', 'Not Related: There is no reasonable possibility that the event may have been caused by the study', 'drug', 'Related:', 'There is a reasonable possibility that the event may have been caused by the study', 'drug', 'A list of factors to consider when assessing the relationship of AEs or SAEs to study drug is', 'provided in Appendix 4.', 'The investigator should justify the causality assessment of each SAE.', 'Relationship of Adverse Events to Study Conduct:', 'The relationship of AEs or SAEs to study conduct will be assessed by the investigator, and will be', 'a clinical decision based on all available information. The following question will be addressed:', 'Is there a reasonable possibility that the AE or SAE may have been caused by study conduct?', 'Regeneron Pharmaceuticals, Inc.', 'Page 92 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}